Navigation Links
Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
Date:11/8/2007

TOKYO and RIDGEFIELD, Conn., Nov. 8 /PRNewswire/ -- Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. (a subsidiary of Boehringer Ingelheim Corporation) announced today that the two companies have reached a settlement agreement with Ranbaxy to enter into a stipulation of dismissal of the pending U.S. litigation with regard to U.S. Patent No. 4,703,063 for Flomax(R) (tamsulosin hydrochloride) capsules, a treatment for the signs and symptoms of benign prostatic hyperplasia (BPH).

As a result of this settlement, the case will be dismissed without prejudice. The settlement of the litigation provides Ranbaxy with the opportunity to launch a generic tamsulosin hydrochloride product on March 2, 2010, prior to the expiration of pediatric exclusivity if such is granted by the FDA. Further terms of the settlement will not be disclosed.

For more information, please contact:

Kate O'Connor, Communications & Public Relations

Boehringer Ingelheim Pharmaceuticals, Inc.

Tel: 203-791-6250

Mobile: 917-446-7400

Astellas Pharma Inc.

Corporate Communications

Tel: +81-3-3244-3201

Fax: +81-3-5201-7473

http://www.astellas.com


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC
2. Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program
3. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
4. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
6. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
7. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
8. Luminex Corporation Reaches Settlement With Rules Based Medicine, Inc.
9. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
10. Zimmer Announces Settlement of Federal Investigation
11. Martek Announces Settlement of OmegaTech Milestone Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... A study ... completed in an ambulatory surgery center (ASC) with satisfactory clinical and patient-reported outcomes, ... TDR studies. , Jake Lubinski, president of AxioMed, commented on the recent ...
(Date:2/24/2017)... ... February 24, 2017 , ... Chef Jodi Abel has returned from her ... in several cities, she gained a number of delicious recipes and new techniques to ... in South Africa’s Western Cape province. It is internationally renowned for its incredible ...
(Date:2/24/2017)... , Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... authored by its Chairman and CEO, Jim Joyce ... Munich Security Conference last Saturday, Bill Gates ... kill more people than nuclear weapons. Mr. Gates expressed ... U.K. intelligence agencies, that scientific terrorists have access to ...
(Date:2/24/2017)... PARSIPPANY, N.J. , Feb. 24, 2017 /PRNewswire/ ... botanicals and biotechnology are now the fastest growing ... the Specialty Actives in Personal Care: Multi-regional ... market research and management consulting firm Kline. ... using bioprocesses that make them more effective for ...
Breaking Biology Technology:
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
Breaking Biology News(10 mins):